| 查看: 548 | 回复: 0 | ||||
[交流]
SGLT2开始喷了
|
|
日本1个，FDA2个 ema也批了 Approval of Suglat® Tablets, a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan TOKYO, January 17, 2014 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced today that it has obtained the marketing approval of selective SGLT2 inhibitor Suglat® 25mg and 50mg tablets (generic name Ipragliflozin L-Proline; development code: ASP1941, “Suglat”) for the treatment of type 2 diabetes in Japan. Astellas filed an application for approval in March 2013. Suglat is a selective SGLT2 (Sodium-Glucose Co-Transporter 2) inhibitor discovered through a research collaboration and is being jointly developed with Kotobuki Pharmaceutical Co., Ltd.. SGLTs are membrane proteins that exist on the cell surface and transfer glucose into cells. SGLT2 is one subtype of SGLTs and plays a key role in the reuptake of glucose in the proximal tubule of the kidneys. Suglat reduces blood glucose levels by inhibiting the reuptake of glucose by selectively inhibiting SGLT2. Suglat is the first SGLT2 inhibitor approved as a treatment for type 2 diabetes in Japan. The efficacy and safety of Suglat were observed in a Phase III pivotal study in monotherapy and clinical studies used in combination with other hypoglycemic agents (6 types) in Japan.. Astellas will manufacture and sell Suglat and co-promote it with Kotobuki Pharmaceutical Co., Ltd. and MSD K.K.. Astellas expects to provide an additional therapeutic option and further contribute to the treatment of type 2 diabetes by introducing Suglat, an oral hypoglycemic agent with a novel mechanism of action, into the Japanese market. About Type 2 Diabetes Diabetes (medically known as diabetes mellitus) is a disorder in which the body has difficulty regulating its blood glucose (sugar) level. There are two major types of diabetes: type 1 and type 2. Type 2 diabetes (formerly called non-insulin-dependent diabetes mellitus or adult-onset diabetes) is a disorder that is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency. Patients are instructed to increase exercise and diet restrictions, but most require treatment with an anti-diabetic agent to control blood glucose. |
回复此楼» 收录本帖的淘帖专辑推荐
 颛顼药学 |
» 猜你喜欢
谁有人卫版 《毒理学基础》第七版书籍
已经有0人回复
-
26有没有老师想收做定量药理的学生啊
已经有3人回复
-
药物学论文润色/翻译怎么收费?
已经有289人回复
-
26考博申请 学or专
已经有15人回复
-
292药学调剂
已经有1人回复
-
NSCLC脑转移肿瘤模型
已经有0人回复
-
CHP-134这个细胞系哪里有？
已经有0人回复
-
看过往病历，有疑惑请教
已经有3人回复
-
27年环评考试资料
已经有1人回复
找到一些相关的精华帖子，希望有用哦~
有谁了解SGLT2抑制剂怎么测活性么？
已经有8人回复
- 万邦医药950万美元买入SGLT2抑制剂
已经有4人回复
- SGLT2抑制剂Canagliflozin （卡纳格列净）的化合物、晶型、化合物制备和片剂专利
已经有11人回复
点击这里搜索更多相关资源科研从小木虫开始，人人为我，我为人人
